Over a 12‐day period, NLRP3‐overexpressing tumours displayed attenuated tumour growth and reduced final tumour burden in response to regorafenib or 5‐FU treatment, compared to control xenografts (Figure 2H,I). The gene discussed is NLRP3; the disease is neoplasm.